Fremanezumab for episodic migraine in children and adolescents: the evolving landscape of CGRP-targeted therapies Authors: Paige Kalika, Teshamae S. Monteith Published: 2026 Migraine is a highly debilitating, lifelong, neurological disease affecting individuals often from childhood to older age. According to the Global Burden of Disease 2021 Study, migraine is the top neurological cause of disability-adjusted life years (DALYs) in children and adolescents, outranking both stroke and neonatal encephalopathy (1). The impact of migraine in this age group may have deleterious consequences, affecting quality of life, school performance, and resulting in long-term health consequences including disability (1-4). The pediatric pipeline for migraine prevention has been slowed by a paucity of investigations. In addition, there are high placebo response rates seen in pediatric trials which match or exceed the effects of the study drug and therefore result in study findings that are difficult to interpret (3). There are several established migraine preventive treatments, both non-pharmacological and pharmacological interventions, most with little evidence in children. Behavioral measures and healthy habits, including good sleep hygiene, adequate hydration, consistent meals, regular physical activity, healthy weight management, limiting caffeine, avoiding tobacco and alcohol, and addressing stress and mental health, are recommended to improve outcomes (5). As very few medications are FDA-approved for migraine in patients under the age of 18, most treatments are prescribed off-label and obtaining insurance coverage for newer medications can be extremely challenging (3). This past decade has been marked by the introduction of the first migraine-specific preventive treatments. The calcitonin gene-related peptide (CGRP)-targeting therapies have been shown to be safe, tolerable, and effective in numerous adult studies. In 2024, the American Headache Society (AHS) updated its position statement to reflect this, recommending that CGRP-targeting therapies be considered as a first-line approach along with other established options (6). Similarly, the Pediatric and Adolescent Special Interest Group (SIG) of AHS recommends the use of CGRP-targeting therapies in pediatric migraine based on expert consensus in the absence of randomized controlled trials (7). However, access to these treatments has been lacking to date. We review and provide commentary on the landmark SPACE trial, the first randomized controlled trial to evaluate a CGRP-targeting therapy in children and adolescents for migraine prevention. Fremanezumab is a monoclonal antibody targeting the CGRP ligand, FDA-approved for migraine prevention in adults (8,9). The SPACE trial, as detailed by Hershey et al., is a multicenter, parallel-group, randomized, placebo-controlled trial evaluating the efficacy, safety, and tolerability of fremanezumab in children and adolescents with episodic migraine (3). The change from baseline in the average number of migraine days per month was the primary endpoint. This study consisted of 237 participants between the ages of 6 and 17 with a diagnosis of episodic migraine (234 in the full analysis). As such, the SPACE trial was inclusive of the real-world population of children and adolescents with episodic migraine, which incorporated different ages from prepubertal to adolescent stages. The study began with a 28-day baseline period, where participants maintained a headache diary and were permitted to use acute migraine medications, except opioids or barbiturates (3). As in clinical practice, there was significant representation of individuals with higher frequencies of migraine as well as those with a lack of response to other treatments (3). Permitting up to 30% of the participants to continue on a stable dose of no more than two concomitant migraine-preventive medications further enhanced the applicability of the study findings, while limiting that percentage to no more than 30% ensured that the trial was not limited by participants with more intractable migraine burden (3). After 28 days, the patients were randomized into a fremanezumab group and a control group that received monthly injections for the 3-month double-blind period. The fremanezumab group was divided by weight, with patients under 45.0 kg receiving monthly injections of 120 mg and patients 45.0 kg and greater receiving monthly injections of 225 mg. The study met its primary endpoint as fremanezumab significantly reduced the average number of migraine days per month (least-squares mean change from baseline of 2.5 vs. 1.4 for placebo, difference, 1.1; P=0.02) over the 3-month double-blind period (Table 1). Although positive, the finding was modest for the primary outcome measure (difference, 1.1; P=0.02) as well as the secondary measures. However, the impact went beyond migraine days and included change in the number of days per month with headache of at least moderate severity (difference, 1.1; P=0.02). Compared to baseline, the average number of days per month with acute medications was also significantly reduced with fremanezumab as compared to placebo, 2.1 vs. 1.0 (difference, 1.1; P=0.002). While the absolute reduction in monthly migraine days may have been relatively small, the overall impact of fremanezumab across multiple endpoints suggests this therapy is likely to be effective in real-world pediatric populations of migraine. Table 1Key results of the SPACE trial: fremanezumab vs. placebo for pediatric episodic migraine (6–17 years)Outcome domainResultsMigraine burden↓ Monthly migraine days↓ Moderate-severe headache daysResponder ratesNearly 1 in 2 achieved ≥50% reduction in monthly migraine daysAcute medication utilization↓ Acute treatment use daysClinical benefits of fremanezumab in pediatric episodic migraine. Not shown here: disability measured by PedMIDAS did not reach significance, and the P value for PedsQL total score, measuring quality of life, was not reported due to the hierarchical testing procedures. Adapted from Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med 2026;394:243-52 (3). Key results of the SPACE trial: fremanezumab vs. placebo for pediatric episodic migraine (6–17 years) Clinical benefits of fremanezumab in pediatric episodic migraine. Not shown here: disability measured by PedMIDAS did not reach significance, and the P value for PedsQL total score, measuring quality of life, was not reported due to the hierarchical testing procedures. Adapted from Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med 2026;394:243-52 (3). Responder rates complement mean changes in migraine frequency by capturing the proportion of patients who achieve clinically meaningful benefit, providing a patient-centered measure of treatment effectiveness. In the SPACE trial, 47.2% of the participants in the fremanezumab group had a reduction of 50% or more migraine days per month, as compared with 27% of the placebo group (difference, 20.1%; P=0.002). Interestingly, the endpoints were similar to those seen in the HALO-EM trial, suggesting that CGRP biology as a migraine target is similar across the lifespan, at least as early as the onset of school-age years (9). The placebo response rates have been a significant barrier in pediatric trials, documented up to 61% in the CHAMP trial (10). In line with some prior studies, the placebo rate in the SPACE trial was also elevated, but the response to the active drug was nearly twice as high. It is possible that the intervention using materials to minimize the placebo response was successful and should be evaluated for possible replication in other studies (3). In the study, the participants were highly impacted by migraine. The baseline demographics suggested a moderately disabled group of participants with reduced quality of life by PedMIDAS and PedsQL, respectively (11,12). However, the between-group difference in disability reduction was not statistically significant at month 3, as the least-squares mean change in the PedMIDAS total score at month 3 was −21.6 points [95% confidence interval (CI), −28.1 to −15.1] with fremanezumab and −15.3 points (95% CI, −22.0 to −8.7) with placebo (difference, −6.3 points; 95% CI, −13.7 to 1.2; P=0.10). Given the immense potential for disruption by migraine on psychosocial function and school attendance, further work is necessary to explore the long-term impact of anti-CGRP therapies on disability and quality of life in this population. Both doses were considered safe as there were no safety signals detected after analyses of adverse events, physical examinations, vital signs, laboratory measures, and electrocardiograms. The safety and side effect profile of fremanezumab in children and adolescents was found to be similar to that seen in the adult trial of fremanezumab, and most adverse events were mild to moderate in severity (3). Injection-site erythema was the most common adverse event in participants receiving fremanezumab (9.8% vs. 5.4% with placebo). While this is reassuring, CGRP is widely expressed in non-neuronal tissues as well as the central nervous system, and the long-term effect of anti-CGRP monoclonal antibodies (mAbs) in prepubertal and pubertal children is unknown. As animal models have shown that CGRP is involved in bone formation and ossification, there is a theoretical risk that these medications could impact linear growth or bone mass, especially as 40–60% of adult bone mass is acquired during adolescence (7,13,14). Further studies will be helpful to determine actual risk, and growth parameters in children taking anti-CGRP mAbs should be followed closely. An alternative drug, topiramate, has been associated with effects on bone, although these studies were with higher doses in children with epilepsy (15,16). While the risks of anti-CGRP mAbs in children are mainly theoretical, the potential benefits as seen in the adult population, including reduced migraine burden, more favorable side effect profile, and improvement in medication overuse, suggest a largely favorable risk-benefit profile (17,18). Where does fremanezumab fit in the migraine treatment landscape of this age group? Before the approval of fremanezumab in 2025, the only FDA-approved preventive treatment for pediatric migraine was topiramate for ages 12 and up. According to the American Academy of Neurology 2019 Guidelines, topiramate, propranolol, and amitriptyline in conjunction with cognitive behavioral therapy (CBT) have the highest levels of evidence for migraine prevention, which should be considered in addition to lifestyle modification, nutraceuticals, and behavioral interventions (5). The guideline gave a high confidence outcome only to the combination of amitriptyline and CBT, noting that it was more likely than placebo to decrease frequency of migraine or headache days and show at least a 50% reduction in headache frequency (5). Looking at evidence of efficacy in clinical trials published between 2010 and 2019, only flunarizine, which is not available in the United States, and topiramate were found to have level A evidence for preventive treatment of pediatric migraine, with frequently prescribed medications like amitriptyline and sodium valproate at level B, and propranolol, cyproheptadine, and commonly used supplements like magnesium, riboflavin, and coenzyme Q10 getting a level C (19). We recognize there are many migraine treatments with evidence in adults but used off-label in children. Only time will tell how fremanezumab will be positioned among the use of other preventive therapies such as candesartan, other CGRP inhibitors including gepants, and onabotulinumtoxinA for chronic migraine. For optimal migraine control, acute migraine medications approved for pediatric patients include rizatriptan for patients 6 years of age and older and zolmitriptan, almotriptan, and sumatriptan/naproxen sodium for patients aged 12 years and older. Neuromodulatory devices with a pediatric indication for both preventive and acute treatment include remote electrical neuromodulation (REN) from 8 years of age and up, and noninvasive vagus nerve stimulation (nVNS) and single-pulse transcranial magnetic stimulation (sTMS) for ages 12 and older. All other neuromodulation devices are used off-label. Given the relatively benign side effect profile, strong efficacy, and reassuring data in the pediatric population, fremanezumab is an important addition to the treatment armamentarium for pediatric migraine. We believe the choice of fremanezumab in clinical practice should be personalized, and that it is appropriate to consider it among first-line considerations for suitable patients. However, access will likely remain limited in the short-term, as insurance companies slowly add it to their formularies and will likely require prior authorizations, appeals, and documented failures of less expensive interventions, despite the high-quality evidence. Needle phobia, in both pediatric patients and their adult caretakers, is also a likely barrier to care and may require special counseling for more disabled patients who do not respond to oral options. Shared decision-making will need to be utilized to weigh other available preventive treatment options, with factors such as costs and the potential for adverse events associated with traditional drug therapies, including cognitive impairment and weight loss with topiramate, weight gain and sedation with amitriptyline, and dizziness and exercise intolerance with propranolol. Although not yet published, a parallel trial studying children and adolescents with chronic migraine has been completed and presented at the 2026 American Academy of Neurology annual meeting. No significant difference in monthly migraine days was seen between fremanezumab and placebo (−3.8 vs. −3.7, difference −0.1; P=0.8484) (20). The chronic migraine findings represent an outlier because all the CGRP-targeting therapies have been proven effective for migraine prevention in adult studies. We agree with the authors that the distinction between chronic migraine and episodic migraine is rather arbitrary. This may be a limitation of FDA regulations with implications for clinical practice. While other studies are ongoing, it is sensible to also consider fremanezumab in clinical practice for the most disabled populations of pediatric patients with chronic migraine. In addition, a re-evaluation in 6 months may be necessary due to longer periods of time to respond. Moreover, children with migraine and high levels of disability should be considered early for treatment, as there is a potential to limit migraine disease progression with early migraine prevention (21). Trials and investigations involving other CGRP monoclonal antibodies and small-molecule CGRP receptor antagonists, known as gepants, are ongoing (Table 2). The results of these studies are heavily awaited due to the limited but growing evidence for migraine treatments in children and adolescents. Given the encouraging results of the SPACE trial alongside the strong evidence for efficacy seen in adult trials of the other CGRP-targeting therapies, we expect this to be a class effect for episodic migraine and that these drugs will likely show value in the pediatric and adolescent population. Table 2Pediatric clinical trials of CGRP-targeted therapies for migraineDrugCGRP-target/typeAcute vs. preventionEpisodic vs. chronicPopulationClinicalTrials.gov identifierStatus/key notesMonoclonal antibodies to calcitonin gene-related peptide or its receptor ErenumabCGRP receptor monoclonal antibodyPreventionEpisodic migraineAges 6–17NCT03836040Active, not recruitingNCT03832998Completed EptinezumabCGRP ligand monoclonal antibodyPreventionEpisodic migraineAges 6–17NCT05897320RecruitingNCT04965675Recruiting GalcanezumabCGRP ligand monoclonal antibodyPreventionEpisodic migraineAges 12–17NCT03432286Active, not recruitingNCT04616326Active, not recruiting FremanezumabCGRP ligand monoclonal antibodyPreventionEpisodic migraineAges 6–17NCT04458857Completed; positive phase 3 pediatric trialNCT04464707Completed; negative phase 3 pediatric trialCGRP receptor antagonists AtogepantGepantPreventionEpisodic migraineAges 12–17NCT06810505Recruiting RimegepantGepantPreventionEpisodic migraineAges 6–17NCT05156398RecruitingAges 6–17NCT04649242Recruiting UbrogepantGepantAcute treatmentEpisodic migraineAges 6–17NCT05125302Recruiting ZavegepantGepantAcute treatmentHistory of migraineAges 6–11NCT06995729Recruiting; phase IFremanezumab is the first and only CGRP-targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of episodic migraine in pediatric patients aged 6–17 years who weigh ≥45 kg. Other CGRP monoclonal antibodies and gepants remain investigational for pediatric migraine, pending trial results. This table includes interventional efficacy and safety trials registered on ClinicalTrials.gov and is not inclusive of pharmacokinetic studies, dose-finding studies, open-label extension studies, or long-term safety follow-up studies. The zavegepant trial is a phase 1 pharmacokinetic study. Clinical trial status was accessed from ClinicalTrials.gov on May 27, 2026. CGRP, calcitonin gene-related peptide. Pediatric clinical trials of CGRP-targeted therapies for migraine Fremanezumab is the first and only CGRP-targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of episodic migraine in pediatric patients aged 6–17 years who weigh ≥45 kg. Other CGRP monoclonal antibodies and gepants remain investigational for pediatric migraine, pending trial results. This table includes interventional efficacy and safety trials registered on ClinicalTrials.gov and is not inclusive of pharmacokinetic studies, dose-finding studies, open-label extension studies, or long-term safety follow-up studies. The zavegepant trial is a phase 1 pharmacokinetic study. Clinical trial status was accessed from ClinicalTrials.gov on May 27, 2026. CGRP, calcitonin gene-related peptide. The SPACE trial represents the first demonstration of efficacy and tolerability of a migraine-specific preventive therapy targeting CGRP in children and adolescents with episodic migraine. These findings address an unmet need in pediatric migraine care given the very limited treatment options in this age group. Most importantly, this study shows that rigorous trials are possible in pediatric age groups, as opposed to extrapolation of adult studies, and that the strong placebo effect seen in pediatric trials can be mitigated through measures to reduce placebo. Further long-term studies are needed to assess persistent efficacy over time, especially for high-frequency episodic and chronic migraine phenotypes. Supplementary The article’s supplementary files as Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0542/prf